Orphan drug designation granted to Abraxane for pancreatic cancer and Stage IIB-IV melanoma
Abraxis BioScience was granted orphan drug designation by the FDA for its drug candidate, Abraxane for Injectable Suspension (paclitaxel albumin [human]-bound particles for injectable suspension) for the treatment of pancreatic cancer and Stage IIB-IV melanoma.
Your Email Address:
Recipient(s) Email Address:
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
Include a message (optional):
The e-mail address(es) that you supply to use this service will only be used to send the requested article.